Yes, the condition of apnea itself is too diffuse and complex to expect a 20 patient one night study(the drug itself only given on a single night). The downside for apnea was sleep contraction and I believe insomnia, a related subjective complaint, skewed the results. Now what is intriguing to me is another unknown possibility... that is this: recall that a higher dose of CX717 in the ADHD trial seem to effect body mass(like stimulants). Now, what if, a 90 day apnea trial was done that showed significant body mass loss. This is a crucial aspect of why folks have apnea in the first place of the obstructive subtype. The more fat, the worse the apnea is the general adage(not uniform though as their are subtypes within obstructive apnea). But if these folks lost weight due to the ampakine, this would indirectly also effect their apnea over time. But they would have to survive many sleepless nights first=)
This stuff has some impact on apnea but this is the wrong indication. The distracting issue of sleep contraction/insomnia make it a bullseye against ADHD IMHO. RD is also boosted once again as an indication as well.
The ideal patient for this drug in a future apnea trial? A fat one with RD and ADHD!
I'm bullishly optimistic in ADHD and for RD, but management's lack of execution in deal making/fund raising hasn't changed. The time it took to get this data is another F- for Cortex.
And yet, paradoxically, I'm more excited by the technology than ever. Hell, just allow a buyout on the cheap to let the technology flourish in competent hands with money would greatly excite me.
AI
Market Data 
Markets 
